Ms Khadijah N Stanfield, CNM | |
530 1st Ave Ste 10q, New York, NY 10016-6402 | |
(212) 263-7021 | |
Not Available |
Full Name | Ms Khadijah N Stanfield |
---|---|
Gender | Female |
Speciality | Midwife |
Location | 530 1st Ave Ste 10q, New York, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033780077 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367A00000X | Advanced Practice Midwife | F001173 (New York) | Secondary |
176B00000X | Midwife | F001173 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ms Khadijah N Stanfield, CNM 140 Casals Place, Apt. 19h, Bronx, NY 10475 Ph: (347) 449-6573 | Ms Khadijah N Stanfield, CNM 530 1st Ave Ste 10q, New York, NY 10016-6402 Ph: (212) 263-7021 |
News Archive
Future Medicine Ltd has today announced the launch of Neurodegenerative Disease Management – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world.
The monthly announcement of Obamacare's enrollment figures has become an exercise in confirmation bias, starting with the administration itself. Health and Human Services Secretary Kathleen Sebelius noted the "encouraging trends" in yesterday's release, while House Speaker John Boehner opted to highlight its "embarrassing failures." ... The only debate worth having is how to improve enrollment. ... enrollment numbers for Obamacare aren't some referendum on the president's popularity or lack thereof. They're the best way to tell whether the law is working as planned - and how to adjust if it isn't (2/13).
One in 59 children are diagnosed with an Autism Spectrum Disorder, a wide array of conditions affecting a child's social, emotional, and behavioral development.
Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the first patient of the U.S. phase 1 clinical trial has been vaccinated with GTL001, the company's first-in-class therapeutic vaccine candidate against HPV 16/18 infections.
Patients with bipolar disorder have decreased semantic priming, the results of a preliminary study indicate.
› Verified 8 days ago